Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $297 | 6-8 weeks | |
25 mg | $916 | 6-8 weeks | |
50 mg | $1,190 | 6-8 weeks | |
100 mg | $1,860 | 6-8 weeks |
Description | HBV-IN-4, a derivative of phthalazinone, functions as a potent, orally active inhibitor of HBV DNA replication, exhibiting an IC50 value of 14 nM. It effectively induces the formation of genome-free capsids, demonstrating significant anti-HBV potency[1]. |
Targets&IC50 | HBV DNA replication:14 nM (IC50) |
In vitro | HBV-IN-4 (compound 19f; 0-1 μM; 8 days) effectively inhibits relaxed circular [rc] and single-stranded [ss] HBV DNA in a dose-dependent manner in HepG2.2.15 cells. It also decreases capsid-associated DNAs and promotes genome-free capsids, particularly those with accelerated migration phenotype[1]. |
In vivo | HBV-IN-4 (Compound 19f; 50-150 mg/kg; oral administration; twice a day; for 4 weeks; Balb/c male mice) achieves a 2.67 log viral load reduction in the AAV-HBV/mouse model[1]. It exhibits favorable drug characteristics, including low plasma clearance (CL=4.1 mL/min/kg), excellent drug exposure (AUC0-t=49,744 h·ng/L), T1/2 (2.15 hours), and oral bioavailability (F=60.4%) with 20 mg/kg oral administration in mice. HBV-IN-4 also shows good liver exposure distribution[1]. |
Molecular Weight | 479.89 |
Formula | C24H19ClFN5O3 |
Cas No. | 2305897-84-9 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 100 mg/mL (208.38 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.